natgillin/translations-raw huggingface dataset:
• To warn women of childbearing age to not become pregnant because deferiprone may seriously harm the unborn baby 
• posvarilo ženske v rodni dobi, naj ne zanosijo, saj lahko deferipron resno škoduje njihovemu nerojenemu otroku.
Dose (mg, three times/day) 
Odmerek (mg/trikrat/dan)
This metabolite lacks ironbinding capability due to inactivation of the 3-hydroxy group of deferiprone. 
Ta presnovek nima sposobnosti vezave železa zaradi inaktivacije 3-hidroksilne skupine deferiprona.
Instruct the patient to immediately discontinue deferiprone and all other medicinal products with a potential to cause neutropenia. 
Bolnika opozorite na takojšnje prenehanje jemanje deferiprona in vseh drugih zdravil, ki bi lahko povzročila nevtropenijo.
If there is a persistent increase in serum alanine aminotransferase (ALT), interruption of deferiprone therapy should be considered. 
Če se vrednost serumske alanin-aminotransferaze (ALT) neprekinjeno zvišuje, je treba razmisliti o prekinitvi zdravljenja z deferipronom.
Doses of deferiprone in those studies ranged from 50 to 100 mg/kg/day and doses of deferoxamine from 40 to 60 mg/kg/day. 
Odmerki zdravila deferipron v teh študijah so se gibali v razponu od 50 do 100 mg/kg/dan in odmerki deferoksamina od 40 do 60 mg/kg/dan.
The amount of Deferiprone Lipomed that you take will depend on your weight. 
Količina zdravila Deferiprone Lipomed, ki ga boste jemali, je odvisna od vaše telesne mase.
Dose adjustments when used with other iron chelators In patients for whom monotherapy is inadequate, Deferiprone Lipomed may be used with deferoxamine at the standard dose (75 mg/kg/day) but should not exceed 100 mg/kg/day. 
Prilagoditve odmerka pri uporabi z drugimi kelatorji železa Pri bolnikih, pri katerih je monoterapija neprimerna, se zdravilo Deferiprone Lipomed lahko uporablja z deferoksaminom v standardnem odmerku (75 mg/kg/dan), vendar ne sme preseči 100 mg/kg/dan.
The MAH shall ensure that in each Member State where Deferiprone Lipomed is marketed, all patients/carers who are expected to use Deferiprone Lipomed are provided with the Patient/Carer reminder card as a part of the outer packaging. 
Imetnik dovoljenja za promet zagotovi, da v vsaki državi, v kateri je Deferiprone Lipomed na trgu, vsi bolniki/skrbniki, za katere se pričakuje, da bodo uporabljali to zdravilo, prejmejo opozorilno kartico za bolnika/skrbnika, katere besedilo je del zunanje ovojnine.
The active substance is deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a bidentate ligand which binds to iron in a 3:1 molar ratio. 
Zdravilna učinkovina je deferipron (3-hidroksi-1,2-dimetilpiridin-4-on), bidentaten ligand, ki veže železo v molskem razmerju 3:1.
This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken deferiprone in clinical studies. 
To stanje, znano kot huda nevtropenija ali agranulocitoza, se je pojavilo pri 1 do 2 od 100 ljudi, ki so jemali deferipron v kliničnih študijah.
Regardless of the degree of renal impairment, the majority of the dose of deferiprone was excreted in the urine over the first 24 hours as deferiprone 3-O-glucuronide. 
Ne glede na stopnjo ledvične okvare je bil odmerek deferiprona v večini izločen z urinom v prvih 24 urah v obliki deferipron-3-O-glukuronida.
Deferiprone and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p>0.05). 
Deferipron in deferoksamin sta si bila enakovredna pri stabilizaciji ali zmanjševanju količine železa v telesu navkljub neprekinjeni transfuzijski aplikaciji železa pri teh pacientih (brez razlike v deležu pacientov z negativno tendenco pri serumskem feritinu med dvema obravnavanima skupinama pri analizi regresije; p > 0,05).
The patient's neutrophil count should be monitored every week. 
Vsak teden je treba pregledati število nevtrofilcev.
The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count (ANC) is less than 1.5 x 109/l. 
Nevarnost agranulocitoze in nevtropenije je višja, če je osnovno absolutno nevtrofilno število (ANC) manjše od 1,5 x 109/l.
In view of the genotoxicity results, a carcinogenic potential of deferiprone cannot be excluded (see section 5.3). 
Glede na rezultate genotoksičnosti se ne izključuje možnosti karcinogenega delovanja deferiprona (glejte poglavje 5.3).
Pharmacotherapeutic group: Iron chelating agents, ATC code: V03AC02 
Farmakoterapevtska skupina: Kelirajoča sredstva za zdravljenje akutnih zastrupitev z železom, oznaka ATC: V03AC02
If you become pregnant while taking Deferiprone Lipomed, stop taking the medicine immediately and tell your doctor. 
Če med jemanjem zdravila Deferiprone Lipomed zanosite, nemudoma prenehajte z jemanjem zdravila in o tem obvestite zdravnika.
Subjects were categorized into 4 groups based on estimated glomerular filtration rate (eGFR): healthy volunteers (eGFR ≥ 90 mL/min/1.73m2), mild renal impairment (eGFR 60-89 mL/min/1.73m2), moderate renal impairment (eGFR 30-59 mL/min/1.73m2), and severe renal impairment (eGFR 15-29 mL/min/1.73m2). 
Preskušanci so bili razvrščeni v 4 skupine na podlagi ocenjene hitrosti glomerularne filtracije (eGFR): zdravi prostovoljci (eGFR ≥ 90 ml/min/1,73 m2), blaga levična okvara (eGFR 60-89 ml/min/1,73 m2), zmerna ledvična okvara (eGFR 30- 59 ml/min/1,73 m2) in huda ledvična okvara (eGFR 15-29 ml/min/1,73 m2).
Data from the published literature on iron balance studies in patients with thalassaemia major show that the use of deferiprone concurrently with deferoxamine (co-administration of both chelators during the same day, either simultaneously or sequentially, e.g., deferiprone during the day and deferoxamine during the night), promotes greater iron excretion than either drug alone. 
Podatki iz objavljene literature o raziskavah ravnovesja železa pri bolnikih s talasemijo major kažejo, da je uporaba zdravila deferipron sočasno z deferoksaminom (sočasna uporaba obeh kelatorjev v istem dnevu, bodisi hkrati bodisi zaporedoma; npr. deferipron podnevi in deferoksamin ponoči) spodbuja večje izločanje železa kot samo uporaba ene vrste zdravila.
In the event of severe neutropenia or agranulocytosis: 
V primeru resne nevtropenije oziroma agranulocitoze:
Deferiprone Lipomed is an iron chelator, a type of medicine that removes excess iron from the body. 
Zdravilo Deferiprone Lipomed je kelator železa - vrsta zdravila, ki iz telesa odstrani odvečno železo.
Following a dose of 25 mg/kg, lower peak serum concentrations have been detected in patients in the fed state (85 µmol/l) than in the fasting state (126 µmol/l), although there was no decrease in the amount of deferiprone absorbed when it was given with food. 
Po odmerku 25 mg/kg je bila najvišja vrednost koncentracije v serumu nižja pri bolnikih, ki so že jedli (85 μmol/l), kot pri bolnikih, ki so zdravilo vzeli na tešče (126 μmol/l); čeprav se absorpcija deferiprona ni zmanjšala, če je bolnik zdravilo vzel s hrano.
In clinical trials, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis and those episodes resolved once therapy was withdrawn. 
V kliničnih preskušanjih se je tedensko spremljanje števila nevtrofilcev izkazalo za učinkovito pri odkrivanju primerov nevtropenije in agranulocitoze, te epizode pa so izzvenele po prekinitvi zdravljenja.
Prescribers are reminded that the use of doses above 100 mg/kg/day is not recommended. 
Predpisovalci zdravila se morajo zavedati, da uporaba odmerkov, večjih od 100 mg/kg/dan, ni priporočljiva.
If you experience nausea or vomiting, it may help to take your Deferiprone Lipomed with some food. 
Če se pri vas pojavita slabost ali bruhanje, bo morda pomagalo, če vzamete zdravilo Deferiprone Lipomed skupaj s hrano.
Limited data are available on the combined use of deferiprone and deferasirox, and caution should be applied when considering the use of such combination. 
O sočasni uporabi deferiprona in deferasiroksa so na voljo le omejeni podatki, zato je potrebna previdnost pri odločanju o uvedbi takega zdravljenja.
Deferiprone Lipomed in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction (see section 4.2). 
Zdravilo Deferiprone Lipomed je v kombinaciji z drugim kelatorjem (glejte poglavje 4.4) indicirano pri bolnikih s talasemijo major, če je monoterapija s katerim koli kelatorjem železa neučinkovita, ali kadar preprečevanje ali zdravljenje življenjsko nevarnih posledic preobremenitve z železom opravičuje hiter ali intenziven popravek (glejte poglavje 4.2).
Even though agranulocytosis only affects 1 to 2 out of 100 users, it is important to monitor your blood on a regular basis. 
Čeravno za agranulocitozo zboli le 1 do 2 bolnika od 100, redno spremljajte svojo krvno sliko.
Monitoring your white blood cell count with Deferiprone Lipomed 
Spremljanje števila belih krvničk v vaši krvi z zdravilom Deferiprone Lipomed
The higher rate of “Cardiac disorders” reported during combination therapy than monotherapy was possibly due to the higher incidence of pre-existing cardiac disorders in patients who received combination therapy. 
Višja stopnja »srčnih bolezni«, o katerih so poročali med kombinirano terapijo, v primerjavi z monoterapijo, je verjetno posledica večje pojavnosti obstoječih srčnih bolezni pri bolnikih, ki so prejemali kombinirano terapijo.
Clinical studies have demonstrated that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia. 
Klinične študije so pokazale, da je deferipron učinkovit pri spodbujanju izločanja železa in da lahko odmerek 25 mg/kg trikrat na dan prepreči naraščanje akumulacije železa (ocenjeno z merjenjem serumskega feritina) pri bolnikih s talasemijo, ki so odvisni od transfuzije.
If you take more Deferiprone Lipomed than you should There are no reports of acute overdose with deferiprone. 
Če ste vzeli večji odmerek zdravila Deferiprone Lipomed, kot bi smeli Ni poročil o akutnem prevelikem odmerjanju deferiprona.
Film-coated tablet. 
Filmsko obložena tableta
If the patient develops an infection while on deferiprone, therapy should be interrupted and the neutrophil count monitored more frequently. 
Če se pri bolniku, ki jemlje deferipron, razvije okužba, se mora zdravljenje prekiniti in pogosteje preveriti število nevtrofilcev.
Deferiprone has been shown to cause neutropenia, including agranulocytosis. 
Dokazano je, da deferipron povzroča nevtropenijo, tudi agranulocitozo.
After starting Deferiprone Lipomed therapy, it is recommended that serum ferritin concentrations, or other indicators of body iron load, be monitored every two to three months to assess the long-term effectiveness of the chelation regimen in controlling the body iron load. 
Po pričetku terapije z zdravilom Deferiprone Lipomed je priporočljivo koncentracijo serumskega feritina ali drugih pokazateljev količine železa v telesu meriti na vsake dva do tri mesece, da se lahko določi dolgotrajno učinkovitost zdravljenja s kelacijo pri nadzorovanju količine železa v telesu.
They recovered from these symptoms after discontinuation of deferiprone. 
Ti simptomi so se pri njih popravili po prekinitvi jemanja deferiprona.
Subjects were categorized into 3 groups based on the Child-Pugh classification score: healthy volunteers, mild hepatic impairment (Class A: 5- 6 points), and moderate hepatic impairment (Class B: 7- 9 points). 
Preskušanci so bili razvrščeni v 3 skupine na podlagi rezultata po razvrstitvi Child-Pugh: zdravi prostovoljci, blaga jetrna okvara (razred A: 5-6 točk) in zmerna jetrna okvara (razred B: 7-9 točk).
Data from the pooled safety database from clinical trials (1343 patient-years exposure to deferiprone monotherapy and 244 patient-years exposure to deferiprone and deferoxamine) showed statistically significant (p<0.05) differences in the incidence of adverse reactions based on System Organ Class for “Cardiac disorders”, “Musculoskeletal and connective tissue disorders” and “Renal and urinary disorders”. 
Podatki iz združenih varnostnih podatkov iz kliničnih preskušanj (1343 bolnikov-let izpostavljenosti monoterapiji s deferipronom in 244 bolnikov-let izpostavljenosti deferipronu in deferoksaminu) so pokazali statistično značilne razlike (p<0,05) v pojavnosti neželenih učinkov glede na organske sisteme, in sicer za »srčne bolezni«, »bolezni mišično-skeletnega sistema in vezivnega tkiva« in »bolezni sečil«.
Coating: hypromellose, macrogol 6000, titanium dioxide 
Obloga: hipromeloza, makrogol 6000, titanov dioksid.
This medicine contains less than 1 mmol sodium (23 mg) per tablet and that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni, da je „brez natrija“.
• To increase patient awareness of the significance of any symptoms of infection while taking Deferiprone Lipomed 
• izboljšalo obveščenost bolnika o pomembnosti kakršnega koli simptoma vnetja med jemanjem zdravila Deferiprone Lipomed,
• To increase patient awareness of the importance of regular monitoring of the neutrophil count during treatment with Deferiprone Lipomed 
• izboljšalo obveščenost bolnika o pomembnosti rednega spremljanja števila nevrotrofilcev med jemanjem zdravila Deferiprone Lipomed,
Limited information is available regarding re-challenge. 
O ponovni uporabi zdravila je na voljo malo podatkov.
Deferiprone is rapidly absorbed from the upper part of the gastrointestinal tract. 
Deferipron se hitro absorbira iz zgornjega dela prebavnega trakta.
If taken during pregnancy, Deferiprone Lipomed may seriously harm the unborn baby. 
Če boste zdravilo Deferiprone Lipomed jemali med nosečnostjo, bo lahko resno škodovalo vašemu nerojenemu otroku.
Fertility No effects on fertility or early embryonic development were noted in animals (see section 5.3). 
Plodnost Učinki na plodnost ali zgodnji razvoj ploda pri živalih niso bili zabeleženi (glejte poglavje 5.3).
The observed incidence of the less severe form of neutropenia (neutrophils <1.5 x 109/l) is 4.9% (2.5 cases per 100 patient-years). 
Opažena pojavnost manj resne oblike nevtropenije (vrednost nevtrofilcev < 1,5 x 109/l) je 4,9 % (2,5 pojavov bolezni na 100 bolnikov-let).
Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in in vitro assays and in vivo in animals. 
Deferipron ni izkazal neposrednega mutagenega delovanja, vendar pa je in vitro ter in vivo v živalih pokazal klastogene učinke.
The effect of Deferiprone Lipomed in decreasing the body iron is directly influenced by the dose and the degree of iron overload. 
Na učinkovitost zdravila Deferiprone Lipomed pri zmanjševanju količine železa v telesu neposredno vplivata odmerek in stopnja presežne količine železa.
Given that deferiprone can be associated with neutropenia and agranulocytosis, therapy in immunocompromised patients should not be initiated unless potential benefits outweigh potential risks. 
Deferipron je povezan z nevtropenijo in agranulocitozo, zato se zdravljenja ne sme uvesti pri bolnikih, ki imajo prizadet imunski sistem, razen če potencialne koristi prevladajo nad tveganji.
The incidences of “Musculoskeletal and connective tissue disorders” and “Renal and urinary disorders” were lower during combination therapy than monotherapy, whereas the incidence of “Cardiac disorders” was higher during combination therapy than monotherapy. 
Pojavnost »bolezni mišično-skeletnega sistema in vezivnega tkiva« in »bolezni sečil« je bila nižja med kombinirano terapijo kot med monoterapijo, medtem ko je bila pojavnost »srčnih bolezni« višja med kombinirano terapijo kot med monoterapijo.
The most common findings in non-iron-loaded animals at doses of 100 mg/kg/day and above were hematologic effects such as bone marrow hypocellularity, and decreased WBC, RBC and/or platelet counts in peripheral blood. 
Najpogostejši odkriti pojavi pri živalih, neobremenjenih z železom, pri odmerku 100 mg/kg/dan in več, so bili hematološki učinki, kot npr. hipoceličnost kostnega mozga, znižano število belih krvničk, eritrocitov in/ali trombocitov v periferni krvi.
INFORMATION IN BRAILLE Deferiprone Lipomed 500 mg 
PODATKI V BRAILLOVI PISAVI Deferiprone Lipomed 500 mg
HIV positive or other immunocompromised patients No data are available on the use of deferiprone in HIV positive or other immunocompromised patients. 
Bolniki, ki so pozitivni za HIV oziroma imajo drugače prizadet imunski sistem Ni podatkov o uporabi deferiprona pri bolnikih, ki so pozitivni za HIV oziroma imajo drugače prizadet imunski sistem.
Aluminium/PVC-PVDC blisters in cartons of 100 film-coated tablets. 
Pretisni omoti iz aluminija/PVC-PVDC v škatlah po 100 filmsko obloženih tablet
You must use effective contraception while you are taking Deferiprone Lipomed. 
Med jemanjem zdravila Deferiprone Lipomed morate uporabljati učinkovito kontracepcijo.
However, chelation therapy may not necessarily protect against iron-induced organ damage. 
Vendar pa ni zanesljivo, da bo terapija s keliranjem zaščitila organe pred poškodbami, ki jih povzroča železo.
PATIENT/CARER REMINDER CARD ((Front Cover)) 
OPOZORILNA KARTICA ZA BOLNIKE/SKRBNIKE ((Sprednja stran ovojnine))
Do not take Deferiprone Lipomed if you are pregnant or if you are trying to become pregnant. 
Zdravila Deferiprone Lipomed ne jemljite, če ste noseči ali poskušate zanositi.
Patients should be advised to report immediately to their physician any symptoms indicative of infection such as fever, sore throat or flu-like symptoms. 
Bolnikom je treba svetovati, naj nemudoma obvestijo zdravnika o vseh simptomih, ki kažejo na okužbo, kot so zvišana telesna temperatura, vneto grlo ali simptomi, podobni gripi.
Phone number: +49 7621 1693 472 Fax number: +49 7621 1693 474 Electronic mail: lipomed@lipomed.com 
Telefon: +49 7621 1693 472 Faks: +49 7621 1693 474 E-pošta: lipomed@lipomed.com
There is a small chance that you may develop agranulocytosis (very low white blood cell count) while taking Deferiprone Lipomed, which may lead to a serious infection. 
Obstaja majhna možnost, da boste med jemanjem zdravila Deferiprone Lipomed razvili agranulocitozo (znižanje števila belih krvničk), ki se lahko razvije v resnejše vnetje.
The maximum difference between the LS means of the therapeutic dose and placebo was 3.01 ms (95% one-sided UCL: 5.01 ms), and between the LS means of the supratherapeutic dose and placebo was 5.23 ms (95% one-sided UCL: 7.19 ms). 
Največja razlika med povprečnimi vrednostmi (po metodi najmanjših kvadratov) terapevtskega odmerka in placeba je bila 3,01 ms (enostranska 95-odstotna zgornja meja zaupanja: 5,01 ms), med povprečnimi vrednostmi (po metodi najmanjših kvadratov) supraterapevtskega odmerka in placeba pa 5,23 ms (enostranska 95-odstotna zgornja meja zaupanja: 7,19 ms).
Common side effects (may affect up to 1 in 10 people): - low white blood cell count (agranulocytosis and neutropenia) - headache - diarrhoea - increase in liver enzymes - fatigue - increase in appetite 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): - nizka koncentracija belih krvničk (agranulocitoza in nevtropenija) - glavobol - driska - povečanje jetrnih encimov - utrujenost - povečanje apetita
Deferiprone Lipomed is used to treat iron overload caused by frequent blood transfusions in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. 
Zdravilo Deferiprone Lipomed se uporablja za zdravljenje prenasičenosti z železom, ki jo povzročijo pogoste transfuzije krvi pri bolnikih s talasemijo major, če je trenutna kelacijska terapija kontraindicirana ali nezadostna.
What you need to know before you take Deferiprone Lipomed 
Kaj morate vedeti, preden boste vzeli zdravilo Deferiprone Lipomed
Combination therapy with deferoxamine is not recommended when monotherapy with either chelator is adequate or when serum ferritin falls below 500 µg/l. 
Sočasno zdravljenje z deferoksaminom ni priporočljivo, če je monoterapija s katerim koli kelatorjem ustrezna ali če feritin v serumu pade pod 500 µg/l.
Deferiprone AUCs did not differ between treatment groups, but Cmax was decreased by 20% in mildly or moderately hepatically impaired subjects compared with healthy volunteers. 
Vrednost AUC deferiprona pri različnih skupinah se ni razlikovala, vrednost Cmax pri bolnikih z blago ali zmerno jetrno okvaro pa je bila zmanjšana za 20 % v primerjavi z zdravimi prostovoljci.
Neurological disorders have been observed in children treated with more than 2.5 times the maximum recommended dose for several years but have also been observed with standard doses of deferiprone. 
Kronično preveliko odmerjanje in nevrološke motnje Nevrološke motnje so opazili pri otrocih, ki so jih nekaj let zdravili z več kot 2,5-kratnim najvišjim priporočenim odmerkom, opazili pa so jih tudi pri standardnih odmerkih deferiprona.
In humans, deferiprone is eliminated mainly via the kidneys; 75% to 90% of the ingested dose is reported as being recovered in the urine in the first 24 hours, in the form of free deferiprone, the glucuronide metabolite and the iron-deferiprone complex. 
Kot kažejo poročila, se od 75 % do 90 % zaužitega odmerka pojavi v urinu v prvih 24 urah, in sicer v obliki prostega deferiprona, glukuronidnega presnovka in kompleksa železo-deferipron.
Abdominal pain Vomiting 
Bolezni prebavil navzea abdominalna bolečina bruhanje driska
No effects on fertility or early embryonic development were noted in non-iron-loaded male and female rats that received deferiprone orally at doses of up to 75 mg/kg twice daily for 28 days (males) or 2 weeks (females) prior to mating and until termination (males) or through early gestation (females). 
Na podganah, ženskega in moškega spola, ki niso bile obremenjene z železom in so prejemale deferipron peroralno v odmerkih do 75 mg/kg dvakrat dnevno 28 dni (samci) ali 2 tedna (samice) pred parjenjem, in do terminacije (samci) ali skozi zgodnjo gestacijo (samice), učinka na plodnost ali zgodnji razvoj ploda ni bilo zaznati.
Very common side effects (may affect more than 1 in 10 people): - abdominal pain - nausea - vomiting - reddish/brown discoloration of urine 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov): - trebušne bolečine - slabost - bruhanje - rdečkastorjav urin
Tablet core: hypromellose, croscarmellose sodium, silica, colloidal anhydrous, microcrystalline cellulose, magnesium stearate 
Jedro tablete: hipromeloza, premreženi natrijev karmelozat, brezvodni koloidni silicijev dioksid, mikrokristalna celuloza, magnezijev stearat.
To monitor for neutropenia, your doctor will ask you to have a blood test (to check your white blood cell count) performed regularly, as frequently as every week, while you are being treated with Deferiprone Lipomed. 
Med zdravljenjem z zdravilom Deferiprone Lipomed vas bo vaš zdravnik redno (vsak teden) naročal na krvne teste (za preverjanje koncentracije belih krvničk) z namenom nadziranja pojava nevtropenije.
The most serious adverse reaction reported in clinical trials with deferiprone is agranulocytosis (neutrophils <0.5 x 109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4). 
Najresnejši neželen učinek zdravljenja v kliničnem preskušanju deferiprona je bila agranulocitoza (vrednost nevtrofilcev < 0,5 x 109/l) s pojavnostjo 1,1 % (0,6 pojavov bolezni na 100 bolnikov-let zdravljenja) (glejte poglavje 4.4).
• History of agranulocytosis. 
• Anamneza agranulocitoze
Deferiprone use should be discontinued if neurological disorders are observed (see sections 4.8 and 4.9). 
Če se pojavijo nevrološke motnje, je treba prenehati z uporabo deferiprona (glejte poglavji 4.8 in 4.9).
Marketing Authorisation Holder and Manufacturer Lipomed GmbH 
Imetnik dovoljenja za promet z zdravilom in izdelovalec Lipomed GmbH